Medigen Vaccine Biologics said Friday that a pediatric nasal-spray influenza lot passed Food and Drug Administration inspection and will ship to Taichung and Tainan clinics enrolled in the autumn immunization drive for children ages two through twelve.
The spray uses a live attenuated formulation Medigen licensed from a U.S. biotech partner and fills locally in its Zhubei plant. Parents who prefer needle-free options have complained for years that Taiwan imported only a fraction of available nasal doses, leaving public pediatricians to rely on shots during peak fever season.
What approval covers
The cleared lot totals 120,000 doses, enough for roughly six weeks at pilot clinics before a mid-December replenishment batch finishes testing. FDA inspectors focused on cold-chain logs after a unrelated plant deviation last spring; Medigen said no deviations occurred on the nasal line.
Centers for Disease Control officials said nasal doses will carry the same government subsidy as injectable vaccines, with coins redeemable at convenience stores under the expanded health coin program rolling out this month.
Clinical considerations
Pediatricians cautioned that asthmatic children and immunocompromised patients should still receive inactive shots. Medigen’s patient leaflet lists a fourteen-day window to avoid other live vaccines, matching international guidance.
Hospital pharmacists in Taichung said demand surveys show parents accept nasal delivery for school-age kids but prefer shots for toddlers who resist sprays. Clinics will stock both forms to avoid wasted appointments.
Supply outlook
Medigen shares rose modestly in Friday trading, though analysts noted influenza revenue remains small compared with the company’s COVID-19 legacy lines. Competitor Adimmune continues to supply injectable doses nationwide; the CDC said total flu coverage targets four million administrations by January, unchanged from last season’s goal.
If the pilot reduces no-show rates, the health agency may expand nasal allocation to Taipei in January. Medigen must submit monthly adverse-event summaries as a condition of accelerated lot release.
Insurance and school clinics
National Health Insurance administrators said school-based clinics in the two pilot cities will receive separate cold-chain shipments so nurses can store sprays alongside injectable syringes without opening the main hospital pharmacy queue. Parent consent forms will note the live-virus composition in plain language after some schools requested bilingual inserts last season.
Private insurers told brokers they will not treat nasal administration as an experimental benefit, clearing the way for corporate wellness packages to include family appointments without rider fees.
Clinic managers said they will track no-show rates weekly and share anonymized totals with the CDC to decide January expansion.
